Down-regulated expression of NPM1 in IMS-M2 cell line by (-)-epigallocatechin-3-gallate.

Hoang Thanh Chi; Bui Thi Kim LY; Hoang Anh VU; Yuko Sato; Phu Chi Dung; Phan Thi Xinh

Return

Down-regulated expression of NPM1 in IMS-M2 cell line by (-)-epigallocatechin-3-gallate.

Author: Hoang Thanh CHI ¹ ; Bui Thi Kim LY ² ; Hoang Anh VU ³ ; Yuko SATO ⁴ ; Phu Chi DUNG ¹ ; Phan Thi XINH ⁵ ;
Author Information

1. Department of Molecular Cytogenetics, Hematology and Blood Transfusion Hospital in Ho Chi Minh City, Ho Chi Minh, Vietnam.
2. Department of Medical Genome Sciences, Graduate School of Frontier Sciences, the University of Tokyo, Tokyo, Japan.
3. Center for Molecular Biomedicine, The University of Medicine and Pharmacy-Ho Chi Minh City, Ho Chi Minh, Vietnam.
4. Basic nursing science, The Japanese Red Cross College of Nursing Japan, Tokyo, Japan.
5. Department of Molecular Cytogenetics, Hematology and Blood Transfusion Hospital in Ho Chi Minh City, Ho Chi Minh, Vietnam
Publication Type:Journal Article
Keywords: Apoptosis; EGCG; IMS-M2; NPM1
From:Asian Pacific Journal of Tropical Biomedicine 2014;4(7):570-574
CountryChina
Language:English
Abstract:
OBJECTIVETo investigate the inhibited effect of epigallocatechin-3-gallate (EGCG) on the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations.
METHODSCell proliferation assay was performed to test the effects of EGCG on cell growth of IMS-M2 cells harboring the NPM1 mutations. Western blot analysis were performed to test the protein expression of NPM1, AKT, those associated with apoptosis.
RESULTSEGCG can down-regulate the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. Moreover, EGCG also suppressed the cell proliferation and induced apoptosis in IMS-M2 cells.
CONCLUSIONSThe results suggested that EGCG could be considered as a reagent for treatment of AML patients with NPM1 mutations.